Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer.

Trial Profile

Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2015

At a glance

  • Drugs Exemestane (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Dec 2014 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019 as reported by ClinicalTrials.gov record.
    • 09 Jul 2013 Planned end date changed from 1 Jun 2015 to 1 Jun 2017 as reported by ClinicalTrials.gov.
    • 06 Feb 2012 Results published in Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top